Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06895343
PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-04-03

Completion Date

2026-11

Last Updated

2026-03-02

Healthy Volunteers

Yes

Interventions

DRUG

ABBV-701

Subcutaneous

DRUG

Placebo

Subcutaneous

DRUG

ABBV-701

IV Infusion

DRUG

Placebo

IV infusion

Locations (2)

CenExel ACT- Anaheim Clinical Trials /ID# 278431

Anaheim, California, United States

Acpru /Id# 273354

Grayslake, Illinois, United States